Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1997;29:525-530

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manolis, A. J.
Right arrow Articles by Gavras, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manolis, A. J.
Right arrow Articles by Gavras, H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CAPTOPRIL
*CLONIDINE
Medline Plus Health Information
*Heart Failure

(Hypertension. 1997;29:525.)
© 1997 American Heart Association, Inc.


State-of-the-Art-Lecture

Combined Sympathetic Suppression and Angiotensin-Converting Enzyme Inhibition in Congestive Heart Failure

Athanasios J. Manolis; Christoforos Olympios; Maria Sifaki; Stelios Handanis; Dennis Cokkinos; Margaret Bresnahan; Irene Gavras; Haralambos Gavras

From the Hypertension Clinic of the Department of Cardiology, Tzanio Hospital, Piraeus, Greece (A.J.M., C.O., M.S., S.H., D.C.), and the Hypertension and Atherosclerosis Section of the Department of Medicine, Boston University School of Medicine, Mass (M.B., I.G., H.G.).

Correspondence to Haralambos Gavras, MD, Chief, Hypertension and Atherosclerosis Section, Boston University School of Medicine, 80 East Concord Street, Boston, MA 02118. E-mail hgavras{at}med-mail.bu.edu

Neurohormonal activation is a pathogenic contributor and prognostic marker in congestive heart failure (CHF). While angiotensin-converting enzyme (ACE) inhibition is now first-line therapy, sympathetic inhibition has only lately been proposed to this aim. Recently, we reported improvement of preload parameters by sympathetic suppression with clonidine. In the present paper we studied the effects of a single oral dose of clonidine 0.15 mg+captopril 6.25 mg combination, compared with captopril 6.15+placebo in a single-blind parallel study on 16 patients with Class III or IV CHF (13 males, 3 females, aged 62±8 years, with an ejection fraction of 33±8%). Hemodynamic and hormonal measurements were taken at baseline after a diagnostic cardiac catheterization and again 2 hours after treatment. The results indicate that preload parameters such as RAP, PCWP and MPAP decreased significantly with the combination therapy but not with captopril alone. On the contrary, SVR decreased significantly with both treatments and SVI increased significantly with both—but the latter change was significantly greater with the captopril/clonidine combination than with captopril alone. Suppression of plasma norepinephrine occurred with the combination only (evidently attributable to clonidine), whereas plasma renin activity increased with both regimens, due apparently to captopril.

Our results indicate that the combination of clonidine with captopril induces significant improvements in both preload and afterload parameters of CHF and correction of activated neurohormones, suggesting additive hemodynamic and hormonal benefits from the two treatment modalities.


Key Words: clonidine • captopril • preload reduction • afterload reduction

Abbreviations: ACE = angiotensin-converting enzyme • AVP = arginine-vasopressin • CHF = congestive heart failure • CO = cardiac output • E = epinephrine • EF = ejection fraction • MAP = mean arterial pressure • MPAP = mean pulmonary artery pressure • NE = norepinephrine • PCWP = pulmonary capillary wedge pressure • PRA = plasma renin activity • RAP = right arterial pressure • RAS = renin-angiotensin system • SNS = sympathetic nervous system • SVI = stroke volume index • SVR = systemic vascular resistance




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
C.-D. Kao, J.-B. Chang, J.-T. Chen, Z.-A. Wu, D.-E Shan, and K.-K. Liao
Hypotension Due to Interaction Between Lisinopril and Tizanidine
Ann. Pharmacother., November 1, 2004; 38(11): 1840 - 1843.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. S. Akers and L. A. Cassis
Presynaptic modulation of evoked NE release contributes to sympathetic activation after pressure overload
Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2151 - H2158.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Grassi, C. Turri, G. Seravalle, G. Bertinieri, A. Pierini, and G. Mancia
Effects of Chronic Clonidine Administration on Sympathetic Nerve Traffic and Baroreflex Function in Heart Failure
Hypertension, August 1, 2001; 38(2): 286 - 291.
[Abstract] [Full Text] [PDF]